Business Context and Reporting Period
This Form 8-K Current Report, filed on July 16, 2020, covers events occurring between July 12 and July 16, 2020, for Scholar Rock Holding Corp (SRRK). The filing details significant executive leadership transitions, including the resignation of the President and CEO, the appointment of a new CEO, and the appointment of a new Chief Financial Officer (CFO).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and executive compensation arrangements.
Material Changes and Executive Transitions
- CEO Resignation: Nagesh K. Mahanthappa, Ph.D., resigned as President and CEO and from the Board, effective August 1, 2020. The resignation was not due to any disagreement with the Company.
- CEO Appointment: Tony Kingsley was appointed President and CEO, effective August 1, 2020. He served as CEO Elect from July 14 to July 31, 2020.
- CFO Appointment: Edward H. Myles resigned from the Board (including Audit Committee Chair) effective July 16, 2020, to assume the role of CFO and Head of Business Operations.
- Board Committee Changes: Michael Gilman became Audit Committee Chair; Kristina Burow became Compensation Committee Chair.
Compensation, Guidance, and Risks
Executive Compensation Packages
| Executive | Role | Base Salary | Target Bonus | Equity Grant | Severance (No Cause/Good Reason) |
|---|---|---|---|---|---|
| Tony Kingsley | President & CEO | $520,000 | 50% of base | 429,684 shares (4-year vest) | 12 months salary + bonus (18 months if Change in Control) |
| Edward H. Myles | CFO | $430,000 | 40% of base | 250,000 shares (4-year vest) | 9 months salary + bonus (1x salary+bonus if Change in Control) |
| Nagesh K. Mahanthappa | Scientific Advisor | $42,916.67/month | Target $257,500 (2020) | Existing awards continue vesting | N/A (Consulting Agreement) |
Outlook and Risks
The filing does not provide updated financial guidance or operational outlook. The primary risk disclosed relates to the leadership transition period. The Company noted that Dr. Mahanthappa will remain a consultant through August 2021 to ensure continuity. The filing includes standard indemnification agreements and non-competition provisions for the departing and incoming executives.
Investor Verification Checklist
- Verify the effective dates of the CEO and CFO transitions (August 1, 2020, and July 16, 2020, respectively).
- Review the attached employment agreements (Exhibits 10.1 and 10.2) for specific performance metrics tied to the annual cash bonuses.
- Confirm the vesting schedule details for the new equity grants (25% cliff vesting after one year, followed by quarterly installments).
- Monitor the Company's subsequent filings for any impact of the leadership changes on clinical trial timelines or commercial strategy.